Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of Buy by Brokerages
04:28pm, Tuesday, 23'rd Nov 2021 Dakota Financial News
Equillium, Inc. (NASDAQ:EQ) has been given an average recommendation of Buy by the six brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued []
Brokerages Expect Equillium, Inc. (NASDAQ:EQ) Will Announce Earnings of -$0.34 Per Share
04:20pm, Monday, 15'th Nov 2021 Dakota Financial News
Analysts expect that Equillium, Inc. (NASDAQ:EQ) will report earnings of ($0.34) per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Equillium’s earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.25). Equillium posted earnings per share of ($0.36) in the […]
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
08:00am, Wednesday, 22'nd Sep 2021
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high un
Equillium's Itolizumab Reduces Urine Protein In Lupus Patients
07:32am, Thursday, 12'th Aug 2021
Equillium Inc (NASDAQ: EQ) announced additional data from the Type A portion of the EQUALISE Phase 1b study of itolizumab in systemic lupus erythematosus (SLE) and lupus nephritis (LN). The new dat
Equillium's Single Phase 3 Study In aGVHD To Support US Filing Of Itolizumab
09:10am, Tuesday, 13'th Jul 2021
Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host
EQ Stock Increases Over 7% Pre-Market: Why It Happened
07:12am, Tuesday, 13'th Jul 2021
The stock price of Equillium Inc (NASDAQ: EQ) increased by over 7% pre-market. This is why it happened.
Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application
4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential
06:15am, Saturday, 19'th Jun 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Equillium's Itolizumab Shows Rapid, Durable Responses In Graft-Versus-Host-Disease Patients
09:53am, Friday, 11'th Jun 2021
Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD). The results were presented
Equillium Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease
07:00am, Friday, 11'th Jun 2021
Itolizumab continues to demonstrate favorable safety and efficacy profile
Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases Whole blood and proteomic stabilized blood assay used to elicit clinical p
Equillium to Present at the JMP Securities Life Sciences Conference
08:00am, Wednesday, 09'th Jun 2021
LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, an
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
04:02pm, Thursday, 13'th May 2021
Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus
LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, tod
Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients Presenta
